Quantcast
Last updated on April 25, 2014 at 1:22 EDT

Latest Heptares Stories

2013-12-09 04:21:13

LONDON and BOSTON, December 9, 2013 /PRNewswire/ -- First Human Trial of Novel Small Molecule Drug Derived From Heptares GPCR-Focused Structure-Based Drug Design Platform Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, announces that it has initiated a Phase 1 clinical study of HTL9936, the first fully selective muscarinic M1 receptor agonist to enter clinical development. HTL9936 is an...

2013-09-06 08:22:18

WELWYN GARDEN CITY, England and BOSTON, September 6, 2013 /PRNewswire/ -- Heptares Therapeutics, the leading GPCR drug discovery and development company, notes that it will be presenting at the following scientific conferences and biotech industry events over the coming weeks. 6th CNS Partnering and Deal-making conference [http://www.gtcbio.com/conference/cns-partnering-and-deal-making-overview ] (Boston, MA, USA, 9-10 September) Dan Grau, Heptares' President,...

2013-06-27 04:21:03

WELWYN GARDEN CITY, England and BOSTON, June 27, 2013 /PRNewswire/ -- Initial focus on neuroscience with first-in-class drugs for Alzheimer's disease and schizophrenia Heptares Therapeutics, the leading GPCR drug discovery and development company, today announced it has raised over US$21 million in a Series B financing to advance a clinical pipeline of novel drugs directed towards clinically validated targets for the treatment...

2013-04-29 04:21:17

WELWYN GARDEN CITY, England and BOSTON, April 29, 2013 /PRNewswire/ -- Heptares Therapeutics, the leading GPCR drug discovery and development company, announces it has achieved all milestones in its collaboration with Takeda Pharmaceutical Company. By achieving these milestones, Heptares will receive a significant payment from Takeda, under the terms of the agreement signed by the two companies in 2011. The agreement is focused on a single GPCR target nominated by Takeda...

2013-01-07 08:28:42

WELWYN GARDEN CITY, England and BOSTON, January 7, 2013 /PRNewswire/ -- Heptares Therapeutics, the leading GPCR drug discovery and development company, today announced they have signed an agreement with Cubist Pharmaceuticals, Inc. (Nasdaq: CBST) to collaborate on the research and discovery of new medicines targeting G protein-coupled receptors (GPCRs), which are membrane proteins involved in a broad range of biological processes and diseases. Under the terms of the...

2011-07-14 03:00:00

CAMBRIDGE, England, July 14, 2011 /PRNewswire/ -- Executives from O2h (Cambridge, UK) and Heptares Therapeutics (Welwyn Garden City, UK) signed an agreement to substantially increase the number of FTE chemists provided by O2h to support discovery programmes at Heptares. Dr Miles Congreve, Head of Chemistry at Heptares said, "O2h has been a valuable partner for Heptares and we are happy to further extend our synthetic chemistry team to include a full lab unit at O2h."...

2011-05-31 02:00:00

ALDERLEY PARK and WELWYN GARDEN CITY, England, May 31, 2011 /PRNewswire/ -- AstraZeneca (NYSE: AZN) and Heptares Therapeutics today announced they have entered a four-year collaboration focused on the potential discovery and development of new medicines targeting G-protein coupled receptors (GPCRs). GPCRs are among the largest and most important family of proteins found in the human body, yet they become highly unstable when removed from their natural membrane-bound environments. This...